Esperion Therapeutics Inc.
NEWS
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
Esperion and an investor group led by Oberland Capital Management LLC announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
Esperion announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders.
Esperion announced that the company will participate in analyst-led fireside chats with investors at the following conferences
Esperion today announced that the company will participate in analyst-led fireside chats with investors at the following conferences
Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.
Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.
Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver
Esperion, the Lipid Management Company announced that the company will participate in an analyst-led fireside chat with investors at the Needham & Company 18th Annual Healthcare Conference in New York, NY on Tuesday, April 9, 2019, at 11:20 a.m. Eastern Time.
JOBS
IN THE PRESS